Biohaven (BHVN) Competitors

Biohaven (NYSE:BHVN) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Is BHVN or NUVL more profitable?

Nuvalent's return on equity of -32.58% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-270.65%	-143.70%
Nuvalent	N/A	-32.58%	-30.14%

Do analysts prefer BHVN or NUVL?

Biohaven presently has a consensus target price of $53.75, indicating a potential upside of 278.49%. Nuvalent has a consensus target price of $119.60, indicating a potential upside of 55.73%. Given Biohaven's higher probable upside, research analysts plainly believe Biohaven is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.07
Nuvalent	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09

Does the media favor BHVN or NUVL?

In the previous week, Biohaven had 35 more articles in the media than Nuvalent. MarketBeat recorded 44 mentions for Biohaven and 9 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.06 beat Biohaven's score of -0.05 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	2 Very Positive mention(s)	5 Positive mention(s)	22 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings and valuation, BHVN or NUVL?

Nuvalent is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$846.42M	-$7.66	-1.85
Nuvalent	N/A	N/A	-$260.76M	-$4.90	-15.67

Which has more risk & volatility, BHVN or NUVL?

Biohaven has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in BHVN or NUVL?

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 10.2% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Nuvalent beats Biohaven on 8 of the 14 factors compared between the two stocks.